Esophageal Cancer Pipeline Review H2 2015

1. Esophageal Cancer - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 21-Oct-2015 No. of pages: 355 Single User License: US $2000 Browse more Reports on Cancer therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Esophageal Cancer - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Esophageal Cancer - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: Adaptimmune Limited, Advantagene, Inc., Advaxis, Inc., Amgen Inc., ArQule, Inc., Array BioPharma Inc., Aslan Pharmaceuticals Pte. Ltd., AstraZeneca Plc, ATLAB Pharma SAS, AVEO Pharmaceuticals, Inc., Bayer AG, BoehringerIngelheim GmbH, Celgene Corporation, Celldex Therapeutics, Inc., Cellectar Biosciences, Inc., Cerulean Pharma, Inc., Cyclacel Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Genmab A/S, Glycotope GmbH, Hutchison MediPharma Limited, Ignyta, Inc., ImmunoFrontier, Inc., ImmunoGen, Inc., Immunomedics, Inc., Johnson & Johnson, Karyopharm Therapeutics, Inc., MacroGenics, Inc., Mebiopharm Co., Ltd., MedImmune, LLC, Novartis AG, Omeros Corporation, Omnitura Therapeutics Inc., OncolysBioPharma Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Precision Biologics, Inc., Proteo, Inc., Puma Biotechnology, Inc., Shionogi & Co., Ltd., Spectrum Pharmaceuticals, Inc., Symphogen A/S, Synta Pharmaceuticals Corp., Transgene Biotek Limited, VioQuest Pharmaceuticals, Inc., Virocan Therapeutics Private Limited and Zhejiang BetaPharma Co., Ltd. Drugs Profile Discussed in this Research: 1-BB1, ADXS-HER2, afatinibdimaleate, alpelisib, AMG-337, ATL-101, binimetinib, CDX-1401, Cell Therapy 1 for Oncology, Cell Therapy to Target NY-ESO-1 for Oncology, cetuximabbiobetter, CRLX-101, CYC-140, dacomitinib, DKN-01, durvalumab, elgemtumab, ficlatuzumab, futuximab, ganetespib, gedatolisib, gefitinib, Gene Therapy for Esophageal Cancer, Gene Therapy to Activate p53 for Oncology, HMPL-309, HuMax-TF-ADC, I131-CLR1404, icotinib hydrochloride, IMF-001, IMGN-289, JNJ-42756493, margetuximab, MBP-426 and more.. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Esophageal Cancer - Pipeline Review, H2 2015 Scope For Esophageal Cancer - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Esophageal Cancer - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Esophageal Cancer - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441